Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some mechanism and general safety-counseling themes align with the provided label excerpts, but multiple drug-interaction claims are unsupported or directionally incorrect (e.g., warfarin bleeding-risk framing; atorvastatin decreasing rifampin levels). Several interaction claims (antacids, HRT, erythromycin level increase, gemfibrozil level increase, muscle-damage risk with 'other statins') are not supported by the supplied label text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
12.1 Mechanism of Action; 1 INDICATIONS AND USAGE
Lipitor works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action
Lipitor may increase the levels of digoxin.
7.5 Digoxin
Lipitor may interact with other cholesterol-lowering medications such as niacin or fibrates.
7 DRUG INTERACTIONS; 2.4 Concomitant Lipid-Lowering Therapy
The response states that careful medication management can help minimize the risk of medication interactions with Lipitor.
5.1 Skeletal Muscle; 7 DRUG INTERACTIONS; 17 PATIENT COUNSELING INFORMATION
Lipitor should be taken exactly as prescribed.
17 PATIENT COUNSELING INFORMATION
Unsupported Statements
Lipitor may increase the risk of bleeding when taken with warfarin.
Provided label excerpt states LIPITOR had no clinically significant effect on prothrombin time with chronic warfarin; it does not state increased bleeding risk.
Lipitor may increase the levels of cyclosporine.
Provided label excerpt states cyclosporine (an OATP1B1 inhibitor) can increase atorvastatin bioavailability/AUC; it does not state atorvastatin increases cyclosporine levels.
Lipitor may increase the levels of erythromycin.
Provided label excerpt discusses increased myopathy/rhabdomyolysis risk with erythromycin/other interacting agents; it does not state erythromycin levels increase.
Lipitor may increase the levels of gemfibrozil.
Provided label excerpt addresses concurrent statin-fibrate use/caution; it does not state atorvastatin increases gemfibrozil levels.
Lipitor may decrease the levels of rifampin.
Provided label excerpt states concomitant rifampin (and other inducers) can lead to reductions in atorvastatin concentrations; it does not state atorvastatin decreases rifampin levels.
Lipitor may increase the risk of muscle damage when taken with other statins.
Provided label excerpt increases myopathy risk with specific interacting agents (e.g., cyclosporine, fibric acid derivatives, niacin, strong CYP3A4 inhibitors) but does not support a blanket 'other statins' interaction claim.
Lipitor may decrease the absorption of antacids such as Tums or Rolaids.
No supporting antacid/Tums/Rolaids information is included in the provided label excerpts.
Lipitor may increase the risk of bleeding when taken with other blood thinners such as aspirin or heparin.
Provided label excerpts do not discuss bleeding risk with aspirin or heparin.
Lipitor may increase the risk of bleeding when taken with hormone replacement therapy.
No supporting hormone replacement therapy/bleeding-risk information is included in the provided label excerpts.
A study in the Journal of Clinical Pharmacology found patients taking Lipitor and warfarin had a higher risk of bleeding compared to those taking warfarin alone.
Provided label excerpt for warfarin does not state increased bleeding risk and instead states no clinically significant effect on prothrombin time.
The response indicates Lipitor may increase the risk of muscle damage when taken with other statins.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Lipitor may increase the levels of cyclosporine.
Label Reference
7.3 Cyclosporine
Low
AI Statement
Lipitor may decrease the levels of rifampin.
Label Reference
7.4 Rifamprin or other Induceder of Cytochrome P450 3A4
Low
AI Statement
Lipitor may increase the risk of bleeding when taken with warfarin.
Label Reference
7.7 Warfarin
Important Omissions
Mechanism and lipid-risk framing are incomplete relative to the provided label (e.g., mention of LDL receptor effects and labeled risk reduction endpoints such as myocardial infarction/stroke/revascularization).
Importance:
Moderate
No dosing/administration specifics from the label excerpts beyond generic 'as prescribed' (e.g., labeled dose adjustments/cautions for interacting agents).
Importance:
Moderate
Formal warnings/precautions monitoring language is partially misapplied as 'regular blood tests' for monitoring medication levels, rather than the label-supported approach (e.g., CPK determinations in certain situations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most core counseling (adherence) and some interaction directions are incomplete/incorrect; however, the major unsupported items are interaction-risk framing claims rather than explicit contraindications/dosing instructions. Based on the provided label excerpts, interaction misinformation could still lead to unsafe counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Drug-interaction statements include multiple unsupported or directionally incorrect claims (warfarin bleeding-risk framing; cyclosporine direction; rifampin direction) and several missing/unsupported interactions (antacids, HRT, erythromycin/gemfibrozil levels, aspirin/heparin bleeding risk).
Suggested Improvement
Restrict interaction statements to the specific label-supported effects (e.g., cyclosporine increasing atorvastatin exposure; rifampin reducing atorvastatin concentrations; warfarin prothrombin-time statement) and remove interaction claims not present in the provided excerpts.